Strain Data Sheet
ANIMAL SEARCH SYSTEM
Data update: May 20, 2019
Health Report   PCR Protocol   Thawing Method
embryos / sperm >
  Mouse Marking
Figure
  Order
RBRC No. RBRC01400  
Type TransgeneCartagena  
Species Mus musculus  
Strain name B6D2-Tg(CAG-Ptafr)1Tksh/TkshRbrc  
Former Common name PAFR-Tg, Platelet-activating factor (PAF) receptor transgenic mouse  
H-2 Haplotype No Data  
Background strain Crlj:B6D2F1  
Appearance
 1 Appearance No Data  
Genotype No Data  
Strain development Developed by Dr. Satoshi Ishii at the University of Tokyo in 1997. A transgenic construct containing a guinea-pig PAFR gene under the control of the a chiken beta actin promotor and the CMV immediate early enhancer, was introduced into the pronuclei of fertilized eggs of B6D2F2. The transgenic mice were mated with B6D2F1.  
Strain description Platelet-activating factor (PAF) is a phospholipid mediator with pleiotropic and potent biological effects on a variety of cells and tissues. This transgenic mice showed a bronchial hyperreactivity, increased endotoxin lethality and melanocytic tumorigenesis. This strain is useful to elucidating the pathophysiological roles of PAF and PAFR in vivo.  
Colony maintenance Cross to B6D2F1 (Hemizygote x Crj:B6D2F1)  
Health Report
BRC facility Health Report in the last year and a half

Examination Date Room Rack
Jul 2, 2007 2-検 D
May 8, 2007 2-検 D
May 7, 2007 2-検 D
Mar 5, 2007 2-検 D
Jan 9, 2007 2-検 D
Oct 30, 2006 2-検 D
Aug 29, 2006 2-検 D
Aug 28, 2006 2-検 D
Gene Details
Promoter CAG promoter (CMV-IE enhancer, chicken beta-actin promoter, rabbit beta-globin genomic DNA)  
 1 Symbol Ptafr  
Symbol name platelet-activating factor receptor (guinea-pig)  
Chromosome UN  
Common name PAF receptor, PAFR  
Symbol description No Data  
References EMBO J 1997 Jan 2;16(1):133-42.  
Bronchial hyperreactivity, increased endotoxin lethality and melanocytic tumorigenesis in transgenic mice overexpressing platelet-activating factor receptor.
Research applications No Data  
Specific Term and Conditions The following terms and conditions will be requested by the DEPOSITOR.
The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR.
In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested.
EMBO J., 16, 133-142 (1997).
The RECIPIENT agrees to include the DEPOSITOR/DEVELOPER as a co-author in any publications resulted by the use of the BIOLOGICAL RESOURCE during the first 2 years after deposition by the DEPOSITOR to the RIKEN BRC.  
Additional information
 1 Lab HP (Japanese)  
 2 Genotyping protocol <PCR>  
Depositor Shimizu, Takao (The University of Tokyo, Graduate School of Medicine)  Shimizu, Takao 
Strain Status /
Availability
(Expected delivery)

back Back
RIKEN BioResource Research Center

English page click here ANIMAL SEARCH SYSTEM